Explore Our Areas

Latest News

European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation

FLORENCE (Italy) and NEW YORK, NY, September 20, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline...

The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare

FLORENCE (Italy) and New York, NY, August 30, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline...

Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer

FLORENCE (Italy) and NEW YORK, NY, July 21, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline...

Search Menarini in the world

v

Etiam commodo dui eget wisi. Donec iaculis gravida nulla. Donec quis nibh at felis congue commodo. Etiam bibendum elit eget erat.

Use the key combination "ctrl" + "mouse wheel" or the "+" and "-" buttons at the bottom right to browse the map



menarini for people

Discover our responsibility projects to stand close to people

read more

Follow our blog

Discover our stories from all over the world

Read More

fondazione internazionale menarini

a meeting point for all friends with common ideals towards the progress of sciences for the benefit of mankind.

sergio gorini, foundation’s first president

read more